Transcend Therapeutics
Blake previously led the frontier technology practice at AlleyCorp, where he helped incubate two companies in 2020 that have since raised >$20M in venture capital. He co-wrote the Psychedelic Science Funders Collaborative’s Landscape Report and was a founding advisor to the PSFC Investment Circle.
Transcend Therapeutics
1 followers
Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. We have real-world data showing that our lead product provided significant benefit to >85% of patients with PTSD and depression. We have already advanced our lead compound into an approved Phase II study in PTSD, with plans to expand into depression and other indications.